Drug intelligence / Profile preview

cadonilimab + gemcitabine + cisplatin

Development stage: Preclinical
Lead developer: Kangfang Sainuo Pharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of cadonilimab, a novel tetravalent bispecific antibody targeting both PD-1 and CTLA-4 immune checkpoints, with gemcitabine and cisplatin, which are established chemotherapy agents. The combination leverages cadonilimab's dual immune checkpoint inhibition with the cytotoxic effects of gemcitabine and cisplatin. This regimen is being investigated for various advanced solid tumors, particularly in biliary tract cancers, gastric cancer, and potentially other indications where the individual components have shown efficacy.

Brand names: Kaitani
Other names: candonilimab-West China Hospital-biliary tract cancercandonilimabAK104-201AK-104-201AK 104-201BicureX regimen

Targets

DNAPDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on cadonilimab + gemcitabine + cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cadonilimab + gemcitabine + cisplatin.

Explore the full profile